• English
  • العربية
  • 中文
  • Français
  • Русский
  • Español

You are here

Pain Palliation of Bone Metastases: Production, Quality Control and Dosimetry of Radiopharmaceuticals

IAEA Radioisotopes and Radiopharmaceuticals Series No. 9

English STI/PUB/2042 ¦ 978-92-0-150022-9

141 pages ¦ 36 figures ¦ € 46.00 ¦ Date published: 2023

Download PDF (4.2 MB)

EPUB format available (12.4 MB)


Radionuclide therapy using bone targeting radiopharmaceuticals is an effective palliative care option to reduce pain associated with advanced disease with bone metastases. Over the last 20 years, suitable therapeutic radionuclides are more widely available, meaning that the benefits of pain palliation therapy could reach more patients. This publication provides a broad overview on the current status of radiopharmaceuticals for bone pain palliation. It covers production of radionuclides, identification of bone seeking carrier molecules, preparation of stable complexes, in vitro and in vivo evaluations and dosimetry studies which are part of the development of these radiopharmaceuticals for clinical use. Details on production and quality control of the currently available products, provided here will be of use to scientists involved in the development of these radiopharmaceuticals.

More Information on reusing IAEA copyright material.


IAEA Radioisotopes and Radiopharmaceuticals, Pain Palliation, Bone Metastases, Management, Production, Quality Control, Nuclear Medicine, Radionuclides, Bone Seeking Carrier Molecules, In Vitro and In Vivo Evaluations, Dosimetry Studies, Clinical Use, Patient Selection, Preparation, Recommended Dose, Efficacy of Treatment, Suitable Target Seeking Molecule, Radiotracers, Bone Targeting Agents, Manufacturing Formulae, Design, Lead Molecules, Sustained Availability, Bone Pain Palliation Radiopharmaceuticals, Cancer Cells, Metastatic Bone Sites, Bone Pain Palliation Agents, Bone Seeking Radiopharmaceuticals, Good Manufacturing Practices, Emitting Radionuclides, Pre-Clinical Evaluation, Dosimetry Calculations, Administered Radiopharmaceuticals, Bifunctional Chelating Agent, BFCA, Target Specific Radiopharmaceuticals, TSRs, Targeted Radionuclide Therapy, Prostate Specific Membrane Antigen, PSMA, Development, Review

Related publications

Stay in touch